Tumor-induced osteomalacia associated with a maxillofacial tumor producing fibroblast growth factor 23: report of a case and review of the literature

被引:19
作者
Mori, Yoshiyuki [1 ]
Ogasawara, Toru [1 ]
Motoi, Toru [2 ]
Shimizu, Yuichiro [3 ]
Chikazu, Daichi [1 ]
Tamura, Kazumi [1 ]
Fukumoto, Seiji [3 ]
Takato, Tsuyoshi [1 ]
机构
[1] Tokyo Univ Hosp, Dept Oral Maxillofacial Surg Dent & Orthodont, Tokyo 1138655, Japan
[2] Teikyo Univ, Sch Med, Dept Pathol, Tokyo 173, Japan
[3] Tokyo Univ Hosp, Div Nephrol & Endocrinol, Dept Med, Tokyo 1138655, Japan
来源
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY | 2010年 / 109卷 / 03期
关键词
ONCOGENIC OSTEOMALACIA; FGF23;
D O I
10.1016/j.tripleo.2009.10.052
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Tumor-induced osteomalacia (TIO) is a rare acquired paraneoplastic disease characterized by renal phosphate wasting and hypophosphatemia. Recently, it was reported that tumors associated with TIO produce fibroblast growth factor (FGF) 23, identified as the last member of the FGF family and of which excessive action causes several hypophosphatemic diseases whereas deficient FGF23 activity results in hyperphosphatemic tumoral calcinosis. In this case, although it was difficult to locate the associated tumor, an abnormal mass in the left maxilla was detected by imaging. The tumor was removed by partial resection of the left maxillary alveolar region. Thereafter, serum level of FGF23 rapidly decreased, hypophosphatemia improved, and the clinical symptoms greatly improved. Histopathologic diagnosis of the tumor was phosphaturic mesenchymal tumor, mixed connective tissue variant. Immunohistochemical findings confirmed that the removed tumor produced FGF23. These results indicate that development of osteomalacia in this patient was related to the maxillary tumor, which overexpressed FGF23. (Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109: e57-e63)
引用
收藏
页码:E57 / E63
页数:7
相关论文
共 16 条
[11]  
RENDINA D, 2009, CALCIF TISSUE INT
[12]  
Ruppe MD, 2008, PRIMER METABOLIC BON, P317
[13]   Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia [J].
Shimada, T ;
Mizutani, S ;
Muto, T ;
Yoneya, T ;
Hino, R ;
Takeda, S ;
Takeuchi, Y ;
Fujita, T ;
Fukumoto, S ;
Yamashita, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (11) :6500-6505
[14]   Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia [J].
Takeuchi, Y ;
Suzuki, H ;
Ogura, S ;
Imai, R ;
Yamazaki, Y ;
Yamashita, T ;
Miyamoto, Y ;
Okazaki, H ;
Nakamura, K ;
Nakahara, K ;
Fukumoto, S ;
Fujita, T .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (08) :3979-3982
[15]   Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia [J].
Yamazaki, Y ;
Okazaki, R ;
Shibata, M ;
Hasegawa, Y ;
Satoh, K ;
Tajima, T ;
Takeuchi, Y ;
Fujita, T ;
Nakahara, K ;
Yamashita, T ;
Fukumoto, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (11) :4957-4960
[16]  
Zimering Mark B, 2005, Endocr Pract, V11, P108